NCT04596475View on ClinicalTrials.gov

Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 28, 2021

Primary Completion Date

April 21, 2022

Study Completion Date

April 21, 2022

Conditions
Hepatitis CHepatitis C Virus Infection, Response to Therapy of
Interventions
DRUG

glecaprevir/pibrentasvir (GLE/PIB)

The study intervention consists of a single daily dose of GLE/PIB 100/40 mg (one dose consists of 3 tablets) administered orally; or crushed and administered via a feeding tube if participant is unable to swallow by mouth, for example in the immediate post-operative period. First dose will be administered in the pre-operative period within 4 hours of surgery followed by once daily doses for 7 days total.

Trial Locations (1)

92037

University of California San Diego, San Diego

All Listed Sponsors
lead

University of California, San Diego

OTHER